A double-blind, multi-centre controlled trial of 0.25% oxymetazoline ophthalmic solution in patients with allergic and non-infectious conjunctivitis

A double-blind, multi-centre controlled trial of 0.25% oxymetazoline ophthalmic solution in patients with allergic and non-infectious conjunctivitis

Oxymetazoline (0.025%) ophthalmic solution, 2 drops 4-times daily, was compared with a placebo in the treatment of allergic and non-infectious conjunctivitis. In this 1 week, double-blind, multi-centre study, oxymetazoline proved significantly superior to the placebo (p < 0.001) in providing rapi...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 2(1980), 6 vom: 08., Seite 353-6
1. Verfasser: Breakey, A S (VerfasserIn)
Weitere Verfasser: Cinotti, A A, Hirshman, M, Skowron, R A, Samson, C R, Danzig, M R
Format: Aufsatz
Sprache:English
Veröffentlicht: 1980
Zugriff auf das übergeordnete Werk:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
Schlagworte:Clinical Trial Journal Article Randomized Controlled Trial Imidazoles Placebos Oxymetazoline 8VLN5B44ZY